'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Cipla has increased 7.64% to Rs 7589.44 crore. Sales of Phamaceuticals segment has gone up 7.61% to Rs 7,291.43 crore (accounting for 95.41% of total sales). Sales of New Ventures segment has gone up 9.72% to Rs 350.68 crore (accounting for 4.59% of total sales). Inter-segment sales rose Rs 44.14 crore to Rs 5,267.00 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 3.45% to Rs 1,866.71 crore. PBIT of Phamaceuticals segment rose 2.51% to Rs 1,825.49 crore (accounting for 97.79% of total PBIT). PBIT of New Ventures segment rose 73.70% to Rs 41.22 crore (accounting for 2.21% of total PBIT).
PBIT margin of Phamaceuticals segment fell from 26.28% to 25.04%. PBIT margin of New Ventures segme...
Pleaselogin & subscribe to view the full report.
More Reports
|
|